Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when TEM files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsTempus AI reports Q2 revenue up 22%, raises guidance, announces $1.5B Personalis acquisition
Filed July 30, 2026 · Period ending July 30, 2026 · ~1 min read
Key Changes
-
high
Q2 revenue $382.5M (+22% YoY) with GAAP net income of $5.6M and Adjusted EBITDA of $8.0M, vs. net loss of $42.8M and negative Adjusted EBITDA of $5.6M in Q2 2025; oncology volume up 31%, Data Licensing & Modeling revenue up 36%.
Exhibit 99.1 view on EDGAR → -
high
Raised full-year 2026 revenue guidance to $1.595–$1.605B (~25% growth) and maintained Adjusted EBITDA expectation of ~$65M; guidance excludes impact from pending Personalis acquisition.
Exhibit 99.1 view on EDGAR → -
high
Entered definitive agreement to acquire Personalis for $16.25/share (~$1.5B enterprise value) to integrate NeXT Personal MRD technology; transaction expected to close late Q4 2026 or early 2027.
Exhibit 99.1 view on EDGAR → -
medium
Completed $460M offering of 0.0% convertible senior notes due 2032 (net proceeds $443.1M); used proceeds to repay $207.7M long-term debt, $100M revolving credit facility, and purchase $31.2M capped calls.
Exhibit 99.1 view on EDGAR → -
medium
Received FDA approval for tumor-only xT CDx assay, becoming first lab with FDA companion diagnostic approval for both tumor-only and tumor-normal comprehensive genomic profiling; enables migration to ADLT pricing.
Exhibit 99.1 view on EDGAR →
Summary
Tempus AI disclosed strong Q2 2026 results alongside a transformative acquisition and regulatory milestone. The company swung to GAAP profitability with $5.6M net income and $8.0M Adjusted EBITDA, reversing year-ago losses, while revenue growth accelerated to 22% on robust oncology testing volume and data licensing demand.
Management raised full-year revenue guidance to $1.595–$1.605B and maintained its $65M Adjusted EBITDA target, signaling confidence in the core business trajectory. The $1.5B Personalis acquisition represents a strategic bet on minimal residual disease (MRD) testing, integrating ultrasensitive tumor-informed technology into Tempus' diagnostic platform.
The deal, funded in part by a $460M convertible notes offering, positions the company to expand its oncology monitoring capabilities as MRD testing gains clinical adoption. Separately, FDA approval of the tumor-only xT CDx assay—the first such companion diagnostic clearance—unlocks higher ADLT reimbursement rates and streamlines the testing workflow. Investors should monitor integration execution and whether the Personalis technology drives incremental revenue growth to justify the acquisition premium, as well as the pace of ADLT pricing realization from the FDA approval.
Section-by-Section Diff
Event · Item 7.01 — Regulation FD Disclosure
Tempus AI posted Q2 2026 supplemental financials and CEO/CFO letter on its investor relations website.
Added in current filing · verify on EDGAR →
On July 30, 2026, the Company made available on the “Events” page of its investor relations website at http://investors.tempus.com supplemental financial information for the quarter ended June 30, 2026 and a letter from its Chief Executive Officer and Chief Financial Officer.
Tempus AI published supplemental financial information for the quarter ended June 30, 2026, along with a letter from the CEO and CFO, on its investor relations website. The 8-K does not disclose the actual financial results or content of the letter; it simply announces their availability on the website under Item 7.01 (Regulation FD Disclosure).
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 31, 2026 · How we verify